:
1. Psychotic symptoms that are primarily attributable to a condition other than the AD
causing the dementia.
2. History of major depressive episode with psychotic features during the 12 months
prior to Screening.
3. History of bipolar disorder, schizophrenia, or schizoaffective disorder.
4. Significant or severe medical conditions including pulmonary, hepatic, renal,
hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic,
cardiovascular, or oncologic disease or any other condition that, in the opinion of
the Investigator, could jeopardize the safety of the subject, ability to complete or
comply with the study procedures or validity of the study results.
5. History or high risk of urinary retention, gastric retention, or narrow-angle
glaucoma as evaluated by the Investigator.
6. Prior exposure to KarXT.
7. History of hypersensitivity to KarXT excipients or trospium chloride.
8. Experienced any significant adverse events (AEs) due to trospium.
9. Participation in another clinical study in which the subject received an
experimental or investigational drug within 3 months before Screening or has
participated in more than 2 clinical studies in the 12 months prior to Screening.
Recruiting
